A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography by NISHI, Rie et al.
 A new, simple method for quantifying gemcitabine triphosphate in 
cancer cells using isocratic high-performance liquid chromatography 
 
Rie Nishi, Takahiro Yamauchi, Takanori Ueda 
 
Division of Hematology and Oncology, Faculty of Medical Sciences, University of 
Fukui. 23-3, Shimoaizuki, Matsuoka, Fukui 910-1193, Japan 
 
Corresponding author: 
Takahiro Yamauchi, 
Division of Hematology and Oncology, Faculty of Medical Sciences, University of 
Fukui, 23-3, Shimoaizuki, Matsuoka, Fukui 910-1193, Japan 
TEL: +81-0776-61-3111 
FAX: +81-0776-61-8109 
E-mail: tyamauch@fmsrsa.fukui-med.ac.jp 
Keywords: gemcitabine; gemcitabine triphosphate; isocratic HPLC; cellular 
therapeutic drug monitoring. 
Running title: isocratic HPLC for intracellular dFdCTP quantification 
 1
 Summary 
 
A deoxycytidine analog, gemcitabine (dFdC), is effective for treating solid tumors and 
hematologic malignancies.  After being transported into cancer cells, dFdC is 
phosphorylated to dFdC triphosphate (dFdCTP), which is subsequently incorporated 
into the DNA strand, thereby inhibiting DNA synthesis.  Intracellular dFdCTP is the 
critical determinant for dFdC cytotoxicity, so therapeutic drug monitoring or in vitro 
testing of the capability of cancer cells to accumulate dFdCTP may be informative for 
optimizing dFdC administration.  We have developed a new isocratic-elution HPLC 
method for quantifying dFdCTP in cancer cells.  Samples (500 μl) were eluted 
isocratically using 0.06 M Na2HPO4 (pH = 6.9) containing 20% acetonitrile, at a 
constant flow rate of 0.7 ml/min and at ambient temperature.  Separation was 
performed using an anion-exchange column, TSK gel DEAE-2SW (250 mm x 4.6 mm 
inside diameter, particle size 5 μl, TOSOH Corp.), and monitored at 254 nm.  The 
standard curve was linear with low within-day and inter-day variability.  The lower 
detection limit (20 pmol) was as sensitive as that of the previous gradient-elution 
method.  dFdCTP was well separated from other nucleoside triphosphates. The 
method could measure dFdCTP in cultured or primary leukemic cells treated in vitro 
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 with dFdC.  The method was also applicable to simultaneous determination of 
dFdCTP and cytarabine triphosphate, the results of which demonstrated the ara-CTP 
production augmented by the dFdC pretreatment.  Thus, our isocratic HPLC assay 
method will be of great use because of its sensitivity and simplicity as well as its 
applicability to biological materials. 
 3
 Introduction 
 
Gemcitabine (2′,2-difluorodeoxycytidine, dFdC) is the most important deoxycytidine 
analog to be developed since cytarabine: it has geminal fluorine atoms inserted at the 
2′-carbon of the deoxyribofuranosyl ring.(1,2)  The drug is active against not only 
leukemic cells in vitro but also several experimental solid tumors such as 
non-small-cell lung cancer, small-cell lung cancer, and pancreatic cancer.(3-6)  
Clinically, dFdC has become the standard first-line therapy for patients with advanced 
pancreatic cancer, and it is rapidly becoming incorporated into first-line regimens in 
non-small-cell lung cancer and transitional-cell carcinoma of the bladder.(7-9)  The 
efficacy of dFdC has also been evaluated for leukemic patients.(10,11)  Thus, dFdC is 
now used widely for treating both solid tumors and hematologic malignancies.(7-11)
dFdC is a prodrug that requires intracellular activation.(1,2)  After being 
transported into cancer cells, it is phosphorylated via dFdC monophosphate and 
diphosphate to dFdC triphosphate (dFdCTP), the process of which is catalyzed by 
several kinases including the rate-limiting enzyme deoxycytidine kinase.  dFdCTP is 
incorporated into DNA at the penultimate position and, after the incorporation of one 
or more nucleotides, blocks further elongation of the DNA strand.  The incorporation 
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 of dFdCTP into DNA is strongly associated with the inhibition of further DNA synthesis, 
so intracellular dFdCTP concentration is considered to be the most critical 
determinant of dFdC cytotoxicity.(1,2,12)  
As demonstrated in the case of a similar deoxycytidine analog, cytarabine, the 
critical parameter for predicting the clinical efficacy of a nucleoside analog is not the 
plasma drug concentration but its triphosphate form in the cancer cells.(13-15)  Then, 
pharmacokinetic evaluation of dFdCTP will provide crucial information necessary for 
the scheduling and dosing of dFdC.  The most widely used method for measuring the 
intracellular dFdCTP concentration uses gradient-elution ion-exchange HPLC, which 
was developed by Gandhi et al.(16,17)  This is a sensitive method applicable to the 
measurement of dFdCTP in mononuclear cells and leukemic cells from patients 
receiving dFdC.  However, it requires a complicated computerized system equipped 
with multiple pumps for regulating two different buffers.  Moreover, gradient-elution 
HPLC methods usually induce base-line drift, which might interfere with the 
quantification of the small peak in biological materials.  To overcome these 
disadvantages, we have developed an isocratic-elution HPLC method for measuring 
dFdCTP in cancer cells.  In contrast to the gradient-elution method, the isocratic 
model is simple and inexpensive as it can be run by a single mechanical pump and 
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 induces no base-line drift.  We demonstrate that our method is precise, sensitive, 
and applicable to biological samples. 
 
Materials and Methods 
 
Chemicals 
Na2HPO4, acetonitrile (HPLC grade), phosphoric acid (85%), and perchloric acid 
(60%) were purchased from Nacalai (Kyoto, Japan).  dFdC and dFdCTP were kindly 
provided by Eli Lilly Corp. (Indianapolis, IN, USA).  Cytarabine was purchased from 
Sigma (St. Louis, MO, USA). 
 
Preparation of standard dFdCTP in aqueous solution 
dFdCTP was dissolved in distilled water to make a stock solution (2 mM), from which 
six different concentrations of dFdCTP solution were made.  These standard 
solutions were stored at -80°C before use.  
 
HPLC apparatus and chromatographic condition 
The HPLC apparatus consisted of a pump (CCPM-II; TOSOH Corp., Tokyo, Japan), 
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 an autosampler (AS-8020; TOSOH Corp.), an in-line degasser (SD-8022; TOSOH 
Corp.), and a variable-wavelength detector (UV-8020; TOSOH Corp.).  The system 
was controlled and the data were analyzed using a personal computer installed with 
LC-8020 software (TOSOH Corp.).(14,18)  Samples were eluted isocratically with 0.06 
M Na2HPO4 (pH = 6.9) containing 20% acetonitrile, at a constant flow rate of 0.7 
ml/min and at ambient temperature.  Separation used an anion-exchange column, 
TSK gel DEAE-2SW (250 mm x 4.6 mm inside diameter, particle size 5 μl, TOSOH 
Corp.), and was monitored at 254 nm, the maximum UV absorption of dFdCTP. 
 
Standard curve 
To determine the standard curve for the assay, a 500-μl-aliquot from each diluted 
aqueous solution of standard dFdCTP ranging between 20 pmol and 2 nmol (20 pmol, 
50 pmol, 100 pmol, 200 pmol, 500 pmol 1 nmol, and 2 nmol) was applied to the HPLC.  
The solutions were measured in triplicate on 3 separate days to determine the 
within-day and inter-day variation.  Data were combined and plotted to determine the 
correlation between the amount of dFdCTP and the peak area.  The standard curve 
was fitted by the weighted least-squares linear regression analysis method using the 
equation y=ax+b.  dFdCTP in unknown samples was quantified by extrapolating the 
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 peak area count into the equation of the standard curve. 
 
Cultured or primary leukemic cells 
To validate the applicability of the method to biologic materials, cultured or primary 
leukemic cells were used.  Human leukemia HL60 cells were cultured in RPMI 1640 
medium (Sigma) supplemented with 10% heat-inactivated fetal bovine serum (Sigma) 
in 5% CO2 humidified atmosphere at 37°C.  Primary leukemic cells were obtained 
with informed consent from a patient with chronic lymphocytic leukemia.  Peripheral 
blood (10 ml) was drawn into a heparinized tube and the Ficoll-Paque density gradient 
centrifugation procedure was used to isolate leukemic lymphocytes.(19)  The cultured 
or primary cells, treated or untreated with dFdC, were then washed twice with fresh 
media, followed by centrifugation (400 g, 10 min, 4°C) to collect the cell pellet in a 
microcentrifuge tube.  The cells were added to 200 μl of 0.3 M cold perchloric acid, 
and the mixture was vortexed for 10 s then allowed to stand for 15 min at 4°C.  The 
acidic supernatant was isolated by centrifugation of the sample (15,600 g, 20 s, 4°C), 
followed by neutralization with 100 μl of 0.5 N potassium hydroxide.  After further 
centrifugation (15,600 g, 20 s, 4°C), the neutralized supernatant was obtained as an 
acid-soluble fraction (ASF), a nucleotide pool.(14,18)  The volume of each ASF sample 
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 was adjusted to 700 μl by the addition of water, from which a 500 μl aliquot was 
applied to the chromatographic analysis.  The intracellular concentration of dFdCTP 
was expressed as pmol/107 cells.  The samples were stored at -80°C until analyzed. 
 
Preparation of standard dFdCTP mixed with ASF 
To further confirm that the method was applicable to biologic samples, another set of 
dFdCTP standards was made using an ASF.  Various amounts of dFdCTP stock 
solution were mixed with an ASF extracted from untreated HL60 cells, and the volume 
of the samples was adjusted to 700 μl by the addition of water.  A 500 μl aliquot from 
each dFdCTP-ASF solution was applied to the HPLC to give final amounts of dFdCTP 
that were equivalent to the aqueous solutions described above.  The precision was 
then assessed as within-day and inter-day assay variation for the measurement of 
dFdCTP in the ASF. 
 
Calculations and statistical analyses 
The standard curve was obtained using GraphPad Prism software (GraphPad 
Software Inc., San Diego, CA, USA).  The mean, coefficient of variation (CV) and 
standard deviation for the dFdCTP measurements were obtained using Microsoft 
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 Excel software (Microsoft Corporation, Redmond, WA, USA). 
 
Results 
 
Standard curve and validation 
To determine the standard curve, six standard aqueous solutions of dFdCTP were 
applied in triplicate to our HPLC scheme on 3 separate days.  A linear relation was 
obtained between the amount of dFdCTP present and the peak area (Fig. 1).  The 
within-day and inter-day variabilities were determined at different amounts of dFdCTP 
for validation.  The variations were low, with all %coefficient of variation (%CV) 
values < 10% (Table 1).  The lower and upper limits of quantification, the lowest and 
highest amounts of dFdCTP that gave %CV < 10%, were 20 and 2000 pmol, 
respectively.  The low limit was as sensitive as that of the previous HPLC assay 
method (25 pmol).(16,17)  Thus, these results show that our HPLC method was precise 
and sensitive for quantification of dFdCTP. 
 
Separation of dFdCTP 
To assess the separation of dFdCTP, a mixture of standard nucleotides (CTP, UTP, 
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 ATP, GTP, and dFdCTP) was injected onto the HPLC.  The dFdCTP peak was clearly 
separated from the other nucleotides (Fig. 2A), with a retention time of 93 min.  The 
retention times of standard deoxyribonucleotides (dATP, dCTP, dTTP, dGTP) were 
almost identical to those of the corresponding ribonucleotides (data not shown), which 
did not overlap the dFdCTP peak.   
To see if the present HPLC condition was applicable to the measurement of 
dFdCTP in biological samples, nucleotide pools extracted from leukemic cells were 
applied.  Fig. 2B represents a blank chromatogram of an ASF extracted from 
untreated human leukemia HL60 cells.  Endogenous nucleoside triphosphates (CTP, 
UTP, ATP, and GTP) were clearly separated in the same way (Fig. 2B), as had been 
demonstrated using the mixture of standard nucleotides (Fig. 2A).  The 
chromatogram did not contain any peaks between ATP and GTP that might otherwise 
have interfered with the dFdCTP peak.  When the ASF was co-eluted with the 
standard dFdCTP solution, the peak of dFdCTP was clearly independent of the other 
endogenous peaks of the leukemic nucleotides (Fig. 2C), confirming the applicability 
of the method to biologic samples. 
To further investigate the method’s clinical utility, it was applied to the 
measurement of dFdCTP generated in leukemic cells in vitro.  An ASF was extracted 
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 from HL60 cells after treatment with dFdC, and then applied to the HPLC analysis.  
Even following incubation with the lowest drug concentration for the shortest time 
period, the presence of dFdCTP in the leukemic cells was clear on the chromatogram 
(Fig. 2D).  Thus, these results clearly show that the dFdCTP is separated from the 
nucleotide pool of the biologic material using our HPLC conditions.  
 
Validation of the dFdCTP measurement in biological samples 
To validate our method in biologic samples, it was applied to measuring known 
concentrations of dFdCTP mixed with the ASF extracted from untreated HL60 cells.  
The dFdCTP-ASF solutions were injected onto the HPLC to give final quantities of 
dFdCTP equivalent to those tested in aqueous solution.  Measurements of these 
dFdCTP-ASF solutions at four different amounts (200 pmol, 500 pmol, 1000 pmol, 
2000 pmol) in triplicate were performed on 3 separate days.  The within-day and 
inter-day variabilities (%CV) were 1.3% and 5.7% for 200 pmol, 1.9% and 0.7% for 
500 pmol, 3.6% and 0.4% for 1000 pmol, and 2.2% and 2.2% for 2000 pmol, 
respectively.  Moreover, the peak areas were similar to and well correlated with those 
generated by the dFdCTP-water solutions (Fig. 3).  This indicates that dFdCTP was 
quite stable in the ASF and that its measurement was not disturbed by the 
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 endogenous ASF peaks.  Thus, these results strongly suggest that our HPLC 
method is applicable to the quantification of dFdCTP in biologic samples. 
 
dFdCTP generation in leukemic cells in vitro 
To confirm the applicability of our method to biologic samples, the production of 
dFdCTP in cultured or primary leukemic cells was determined.  When HL60 cells 
was incubated with dFdC in vitro, the accumulation of dFdCTP was time- and 
concentration dependent (Fig. 4A&B).  However, the accumulation was maximized at 
2-5 µM dFdC (Fig. 4B).  Similarly, the concentration- and time-dependent 
accumulation of the intracellular dFdCTP was observed in primary leukemic cells from 
a patient with chronic lymphocytic leukemia (Fig. 4C).  Thus, our HPLC assay 
method could measure the intracellular dFdCTP concentrations in cancer cells. 
 
Separation between cytarabine triphosphate and dFdCTP 
One of the strategies for overcoming the chemo-resistance of leukemia is to augment 
the accumulation of the triphosphate form of the key anti-leukemic drug cytarabine in 
leukemic cells using other nucleoside analogs such as fludarabine or dFdC.(20,21)  
When HL60 cells were treated with dFdC combined with cytarabine, our HPLC  
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 method separated cytarabine triphosphate (retention time 66 min) from dFdCTP (Fig. 
5A&B).  The analysis revealed that the preincubation with dFdC augmented the 
cytarabine triphosphate production by 1.6 fold (Fig. 5C).  Thus, the method is 
capable of simultaneously measuring the triphosphates of these two compounds.   
 
Discussion 
 
We have developed a new, simple and sensitive analytical method for quantifying 
dFdCTP in cancer cells using isocratic HPLC.  dFdCTP was clearly separated from 
adjacent nucleotides (Fig. 1), and the assay variation was low, with %CV < 10% 
(Table 1).  The method is as sensitive as the commonly used gradient-elution method.  
Its applicability to biologic materials was demonstrated by the measurement of 
dFdCTP concentrations in cultured or primary leukemic cells (Fig. 2 and 4).  Our 
HPLC scheme is also applicable to simultaneous determination of dFdCTP and 
cytarabine triphosphate (Fig. 5). 
 The previously reported HPLC method for determining intracellular dFdCTP 
concentration used a Partisil-10 SAX anion-exchange column (250 mm x 4 mm inside 
diameter, Whatman, Inc. Clifton, NJ, USA) and two buffers, buffer A (5 mM NH4H2PO4, 
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 pH = 2.8) and buffer B (0.75 M NH4H2PO4, pH = 3.49).  The separation used a 
concave gradient elution (curve #9) starting with 65% of buffer A and 35% of buffer B 
and finishing with 100% buffer B, at a rate of 3 ml/min for 30 min.(16,17)  Although this 
method takes less running time than ours, it requires a computerized system to 
regulate two pumps.  In contrast, our new isocratic HPLC method uses a single 
buffer and can be controlled not only using a computerized system but also using a 
conventional, mechanical single pump.  Moreover, isocratic elution does not induce 
base-line drift (Fig. 2), so allows accurate measurement of small amounts of dFdCTP 
in crude biologic extracts, which lead to the excellent sensitivity of the present method 
(Fig. 1, Table 1).   
Previous reports demonstrated that in peripheral mononuclear cells or 
leukemic cells dFdCTP accumulation reached a plateau when the plasma dFdC 
concentration exceeded 15-20 µM.(22-24)  Studies with leukemic patients suggested 
that a dose rate of 10 mg/m2/min would produce plasma dFdC concentrations > 20 
µM and maximize the rate of dFdCTP accumulation.(23,25)  In contrast, Fig. 4 
demonstrated the intracellular dFdCTP production was maximized at 2-5 µM dFdC in 
media.  This might be attributed to the difference of the cell types.  The results also 
suggest that the intracellular pharmacokinetics vary among cancers. 
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 dFdCTP successfully augmented cytarabine trihposphate production in HL60 
cells (Fig. 5).  Intracellular dFdCTP inhibits ribonucleotide reductase, an enzyme 
responsible for de novo synthesis of deoxyribonucleotides.  The inhibition of 
ribonucleotide reductase results in a decline in the intracellular dCTP pool, thereby 
decreasing dCTP-mediated feedback inhibition of deoxycytidine kinase.  Enhanced 
deoxycytidine kinase consequently augments production of cytarabine triphophsate.(3)  
Therefore, the present HPLC method would also be useful for pharmacologic 
evaluation of the combination effect between cytarabine and dFdC. 
Clinical studies have been conducted to optimize dFdC therapy by adjusting 
its dose and schedule to obtain the maximum accumulation of dFdCTP in cancer 
cells, since intracellular dFdCTP is critical to dFdC cytotoxicity.(22-25)  Because 
intracellular pharmacokinetics vary widely between patients and cancers,(15) 
therapeutic drug monitoring at an intracellular level may be necessary for better 
individualization.  Moreover, after resection of tumors such as pancreatic cancer 
and lung cancers, in vitro testing of the tumor’s sensitivity to dFdC or its capability to 
accumulate dFdCTP might provide crucial information to guide the decisions about 
adjuvant chemotherapy and regimen selection.(26,27)  In either case, the intracellular 
dFdCTP concentration needs to be determined easily and inexpensively in hospitals 
 16
 on a daily basis.  Thus, for these purposes, our isocratic HPLC method has the 
great advantages of sensitivity and simplicity as well as applicability to biologic 
materials.  
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 Legends 
 
Fig. 1. 
Standard curve for dFdCTP measurement. Various concentrations of standard 
dFdCTP (20, 50, 100, 200, 500, 1,000, and 2,000 pmol ) in aqueous solution were 
applied in triplicate to our HPLC scheme on 3 separate days.  A linear relation was 
obtained between dFdCTP amount and peak area, using all the data sets.  The 
parameters for the curve were: y-intercept = -12.1 ± 4.7, slope = 0.92 ± 0.01 (r2 = 
0.9981, P < 0.0001, for the linear regression line). 
 
Fig. 2.  
HPLC profiles of nucleotides.  (A) Standard nucleotides (ATP, CTP, UTP, GTP, and 
dFdCTP) dissolved in water were applied to our HPLC scheme; (B) an acid-soluble 
fraction was extracted from untreated leukemic HL60 cells (2 × 107 cells), and applied 
to the HPLC; (C) the same acid-soluble fraction was co-eluted with standard dFdCTP; 
(D) an acid-soluble fraction was extracted from HL60 cells after 0.5 h incubation with 
0.1 μM dFdC and applied to the HPLC. 
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 Fig. 3. 
Correlation between dFdCTP measurements in aqueous and ASF solutions.  
Measurements of dFdCTP in water or ASF were performed in triplicate on 3 separate 
days.  The peak area counts were similar and closely correlated (slope = 1.01 ± 0.01, 
y-intercept = 0, x-intercept = 0, r2 = 0.99, P < 0.0001, for the linear regression line). 
 
Fig. 4. 
dFdCTP production in leukemic cells.  (A) HL60 cells (1 × 106 cells/ml, 10 ml) were 
incubated with 0.1 μM (o) or 0.5 μM (●) dFdC for the indicated time periods (0, 0.5, 1.0, 
1.5 h).  Alternatively, (B) the cells were incubated for 1.5 h with the indicated 
concentrations (0, 0.1, 0.2, 0.5, 1.0, 2.0, 5.0 μM) of dFdC.  (C) Primary leukemic cells 
(1 × 106 cells/ml, 10 ml) from a patient with chronic lymphocytic leukemia were 
incubated for 2.0 h (o) or 4.0 h (●) with the indicated concentrations (0, 1.0, 2.0 μM) of 
dFdC.  The samples underwent the extraction of acid soluble fraction, and were 
subsequently analyzed by our HPLC method to determine the intracellular dFdCTP 
concentrations.   
 
Fig. 5. 
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 Separation of cytarabine triphosphate from dFdCTP.  HL60 cells (1 × 106 cells/ml, 10 
ml) were incubated with (B) or without (A) 10 μM dFdC for 2.0 h, followed by washing, 
resuspension in fresh medium, and incubation with 10 μM cytarabine for 3 h.  The 
samples were then applied to the HPLC.  The ara-CTP production was augmented 
by the dFdC preincubation (C). 
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dFdCTP 
(pmol) 
Within-day 
(day 1) 
Inter-day 
Table 1 
Within-day and inter-day variation for dFdCTP in aqueous solution 
Mean 
SD 
%C.V. 
variation
84.4
5.7
6.8
439.8
15.9
3.6
880.6
26.9
3.1
167.9
9.6
5.7
39.7
1.6
4.1
166. 5 
1.7 
1.0 
34.8 
0.2 
0.6 
893.1 
6.5 
0.7 
1800.3 
70.6 
3.9 
1867.0
54.1
2.9
11.0
0.9
8.0
13.0 
0.5 
3.5 
20 
50 
100 
200 
500 
1000 
2000 
439.4 
7.2 
1.6 
81.0 
4.0 
4.9 
Standard aqueous solutions of dFdCTP were measured in triplicate on 3 separate days. The 
within-day variation given is that measured on day 1. The inter-day variation was calculated from 
the mean of each day's peak area count.  
C.V. ; coefficient of variation 
0 500 1000 1500 2000
0
500
1000
1500
2000
dFdCTP (pmol)
A
r
e
a
 
c
o
u
n
t
(A) (B)
(C) (D)
UTP
CTP
ATP
dFdCTP
GTP
dFdCTP
dFdCTP
UTP
CTP
ATP
GTP
A
b
s
o
r
b
a
n
c
e
 
a
t
 
2
5
4
 
n
m
A
b
s
o
r
b
a
n
c
e
 
a
t
 
2
5
4
 
n
m
A
b
s
o
r
b
a
n
c
e
 
a
t
 
2
5
4
 
n
m
A
b
s
o
r
b
a
n
c
e
 
a
t
 
2
5
4
 
n
m
0 50 100
min
0
50
100
150
0 50 100
min
0
20
40
60
80
0 50 100
min
0 50 100
min
0
20
40
60
80
0
5
10
0 500 1000 1500 2000
0
500
1000
1500
2000
dFdCTP-water solution
area count
d
F
d
C
T
P
-
A
S
F
 
s
o
l
u
t
i
o
n
a
r
e
a
 
c
o
u
n
t
(A)
Hours dFdC (μM)
(B)
0.0 0.5 1.0 1.5
0
100
200
300
400
0 1 2 3 4 5
0
250
500
750
1000
0.0 0.5 1.0 1.5 2.0
0
100
200
300
d
F
d
C
T
P
p
m
o
l
/
 
1
0
7
c
e
l
l
s
(C)
dFdC (μM)
d
F
d
C
T
P
p
m
o
l
/
 
1
0
7
c
e
l
l
s
d
F
d
C
T
P
p
m
o
l
/
 
1
0
7
c
e
l
l
s
(A)
A
b
s
o
r
b
a
n
c
e
 
a
t
 
2
5
4
 
n
m
0.0
2.0
4.0
cytarabine
triphosphate
dFdCTP
A
b
s
o
r
b
a
n
c
e
 
a
t
 
2
5
4
 
n
m
(B)
0.0
2.0
4.0
（Ａ）
（Ｂ）
0
100
200
300
400
（Ｃ）
dFdC － +       
A
r
e
a
 
c
o
u
n
t
50 100
50 100
min
min
cytarabine
triphosphate
